Rob Finizio is a successful entrepreneur with over 30 years of experience building public and private companies in the pharmaceutical and medical device industries. Rob co-founded CareFusion in 2001, the market leader in medication patient safety, and sold CareFusion to Cardinal Health (CAH) in 2006. Cardinal Health spun CareFusion out in 2009 (CFN) with a listing on the S&P 500. After CareFusion, Rob co-founded TherapeuticsMD (TXMD) in 2008. As the CEO and Vice Chairman, Rob developed TXMD from a start-up to the Women’s Health Pharmaceutical market leader in drug development proudly the first and only Women’s Health company to have 3 new drugs approved in a single year (2018). In 2011, Rob took TXMD public on the NYSE and achieved a market capitalization of well over a billion dollars. Since inception, Rob raised more than $1 Billion in private / public equity and debt. Currently, Rob is an Executive Director at PleoPharma and General Partner with MintPharma Capital, an early-stage BioTech venture capital fund. Rob sits on the Board of Directors for PleoPharma, Myosin Therapeutics, Vycellix, NOXX Therapeutics, ICaPath and Vycellix. He is the Chairman Emeritus of Bio-Florida.